At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 40 enrolled
Drug / intervention
Raltegravirdrug
Likely dose
Raltegravir 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid
In Brief
A Phase 3 clinical trial evaluating Raltegravir for HIV Infections. Completed, enrolled 40 participants across 1 site.
Detailed Summary
This study is being done to find out how much of the drug raltegravir (RGV) gets into cerebrospinal fluid (CSF), compared to how much get into the blood and to find out if normal changes in a certain gene in your body affects how much RGV gets into the CSF.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2008
First PostedAug 2008
Primary CompletionFeb 2011
Study CompletionAug 2011
TodayJul 2026
First PostedAug 8, 2008
Enrollment StartAug 1, 2008
Primary CompletionFeb 1, 2011
Study CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 17.9 years ago
Interventions
Raltegravirdrug
400mg orally every 12 hours for 7 days